This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: FDA Approvals to MRK, LLY, NVS and GSK's Drugs
by Kinjel Shah
FDA approves expanded labels of Merck (MRK), Novartis (NVS) and Glaxo (GSK) drugs and Lilly's (LLY) new insulin.
PTC Therapeutics Initiates Phase II/III Study for Coronavirus
by Zacks Equity Research
PTC (PTCT) commences a phase II/III study to evaluate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19.
Roche's Tecentriq With Chemotherapy Meets Goal for TNBC
by Zacks Equity Research
Roche's (RHHBY) phase III study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy meets goal in early TNBC patients.
Dr. Reddy's Inks Deal With Gilead Sciences for Remdesivir
by Zacks Equity Research
Dr. Reddy Laboratories (RDY) inks a deal with Gilead to register, manufacture and sell the latter's Remdesivir ??? a potential treatment for COVID-19 ??? in 127 countries including India.
Roche (RHHBY) Presents Positive Data on Venclexta at EHA 2020
by Zacks Equity Research
Roche (RHHBY) provides pipeline updates at the EHA Virtual Congress Press Briefing.
Novartis' (NVS) Beovu Gets FDA Approval for Label Update
by Zacks Equity Research
Novartis' (NVS) ophthalmology drug, Beovu, gets update for safety information regarding retinal vasculitis and retinal vascular occlusion.
Bristol-Myers Gets FDA Nod for Label Expansion of Opdivo
by Zacks Equity Research
Bristol-Myers (BMY) gets FDA nod for Opdivo for the treatment of esophageal squamous cell carcinoma.
RedHill Files CTA for Coronavirus Study on Opaganib in Russia
by Zacks Equity Research
RedHill (RDHL) submits a Clinical Trial Application in Russia for a phase II/III study on opaganib to treat patients detected with severe COVID-19 infection and pneumonia. Stock up.
Karyopharm Starts Dosing in Selinexor Study for Glioblastoma
by Zacks Equity Research
Karyopharm (KPTI) commences a phase I/II study evaluating Xpovio (selinexor) in combination with standard-of-care therapy in patients with newly-diagnosed or recurrent glioblastoma.
Sarepta's Gene Therapy Promising in Muscular Dystrophy Study
by Zacks Equity Research
Sarepta's (SRPT) gene therapy candidate for treating limb-girdle muscular dystrophy shows continued functional improvement over a year for the lower dose as well as increasing efficacy with higher dose.
FibroGen Initiates Phase II/III Study in Severe Coronavirus
by Zacks Equity Research
FibroGen (FGEN) starts a phase II/III study in Italy on pamrevlumab versus standard of care in patients with severe COVID-19 infection.
Global Blood Seeks Label Expansion of Oxbryta in Kids With SCD
by Zacks Equity Research
Global Blood (GBT) seeks label expansion of Oxbryta for the treatment of SCD in children aged 4 to 11 years.
AstraZeneca's Calquence Shows Promise as Coronavirus Treatment
by Zacks Equity Research
Peer-reviewed data on AstraZeneca's (AZN) Calquence shows that it improves laboratory markers of inflammation and decreases oxygen requirements in most patients hospitalized due to COVID-19.
AstraZeneca Reportedly Approaches Gilead for Potential Merger
by Zacks Equity Research
If AstraZeneca (AZN) and Gilead (GILD) were to combine into one, it would be the biggest health-care deal ever.
J&J's Darzalex Subcutaneous Version Gets Approval in Europe
by Zacks Equity Research
J&J (JNJ) announces approval of subcutaneous formulation of Darzalex for all current MM indications in first-line as well as relapsed/refractory multiple myeloma.
Novartis' Asthma Treatment Meets Primary Endpoint in Phase III
by Zacks Equity Research
Novartis (NVS) announces positive results from a late-stage study on Enerzair Breezhaler in patients with asthma.
Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential COVID-19 antibody therapy. FDA grants label expansion approvals to several drugs.
Roche's COVID-19 Test Gets FDA's Emergency Use Authorization
by Zacks Equity Research
Roche's (RHHBY) Elecsys IL-6 test gets FDA's EUA for identifying patients at high risk of severe inflammatory response.
Roche Tecentriq-Avastin Combo Gets FDA Nod for Liver Cancer
by Zacks Equity Research
FDA approves Roche's (RHHBY) sBLA seeking approval of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.
Gilead Down on Mixed Results From Coronavirus Drug Remdesivir
by Zacks Equity Research
Gilead's (GILD) shares decline on mixed results from a late-stage study on coronavirus drug.
Novartis' (NVS) Breast Cancer Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Novartis (NVS) gets positive CHMP opinion for breast cancer drug, Piqray. The company also announces other pipeline updates.
Lilly's Cyramza Gets FDA Approval for First-Line Lung Cancer
by Zacks Equity Research
FDA approves Lilly's (LLY) Cyramza as a combination regimen for metastatic EGFR-mutated non-small cell lung cancer. Cyramza is now approved for six indications to treat four different types of cancers.
The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers
Roche Starts Study on Actemra with Gilead's Drug for Coronavirus
by Zacks Equity Research
Roche (RHHBY) commences a phase III study on Actemra with Gilead's remdesivir in hospitalized patients with severe COVID-19 pneumonia.
FDA Okays Lilly's Alzheimer's Disease Diagnostic Agent Tauvid
by Zacks Equity Research
With the US regulatory agency's nod, Eli Lilly's (LLY) Tauvid became the first and the only approved radioactive diagnostic agent to image tau NFTs in the brain for effectively evaluating AD patients.